Filtered By:
Management: Funding
Therapy: Immunotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 78 results found since Jan 2013.
Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial
This study aimed to evaluate the safety and activity of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK) and Flt3L (Ad-hCMV-Flt3L) in patients with high-grade glioma.METHODS: In this dose-finding, first-in-human trial, treatment-naive adults aged 18-75 years with newly identified high-grade glioma that was evaluated per immunotherapy response assessment in neuro-oncology criteria, and a Karnofsky Performance Status score of 70 or more, underwent maximal safe resection followed by injections of adenoviral vectors expressing HSV1-TK and Flt3L into the tumour bed. The study was conducted at the University of Michigan Me...
Source: Ann Oncol - September 1, 2023 Category: Cancer & Oncology Authors: Yoshie Umemura Daniel Orringer Larry Junck Maria L Varela Molly E J West Syed M Faisal Andrea Comba Jason Heth Oren Sagher Denise Leung Aaron Mammoser Shawn Hervey-Jumper Daniel Zamler Viveka N Yadav Patrick Dunn Wajd Al-Holou Todd Hollon Michelle M Kim D Source Type: research
Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
EClinicalMedicine. 2023 Aug 9;63:102156. doi: 10.1016/j.eclinm.2023.102156. eCollection 2023 Sep.ABSTRACTBACKGROUND: Cancer immunotherapy shows unique efficacy kinetics that differs from conventional treatment. These characteristics may lead to the prolongation of trial duration, hence reliable surrogate endpoints are urgently needed. We aimed to systematically evaluate the study-level performance of commonly reported intermediate clinical endpoints for surrogacy in cancer immunotherapy.METHODS: We searched the Embase, PubMed, and Cochrane databases, between database inception and October 18, 2022, for phase 3 randomised t...
Source: Cancer Control - August 21, 2023 Category: Cancer & Oncology Authors: Zhishan Zhang Qunxiong Pan Mingdong Lu Bin Zhao Source Type: research
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
This study aims to assess the preliminary anti-tumor activity and safety of sintilimab plus bevacizumab, oxaliplatin and capecitabine as a treatment option for patients with RAS-mutant MSS mCRC.METHODS: This study was an open-label, single-arm, phase II trial in China. Patients with unresectable, RAS-mutant and MSS metastatic colorectal adenocarcinoma received treatment by intravenous sintilimab (200 mg, day 1) plus bevacizumab (7.5 mg/kg, day 1), oxaliplatin (135 mg/m2, day 1) and oral capecitabine (1 g/m2, day 1-14) in each 21-day cycle. The primary endpoints included objective response rate (ORR) and adverse events. Bio...
Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Xuefeng Fang Ning Zhu Chenhan Zhong Liuhong Wang Jun Li Shanshan Weng Hanguang Hu Caixia Dong Dan Li Yongmao Song Dong Xu Jianwei Wang Lifeng Sun Jian Wang Zhanhuai Wang Hongfeng Cao Xiujun Liao Ningjuan Yu Qian Xiao Mi Mi Suzhan Zhang Kefeng Ding Ying Yu Source Type: research
Revealing the concealed: A tribute to Donald L. Morton, MD
Clin Exp Metastasis. 2023 Jul 31. doi: 10.1007/s10585-023-10223-9. Online ahead of print.ABSTRACTDonald L. Morton, MD, epitomized one of America's dream scenarios: a person evolving from the humblest of origins to become an international celebrity in his profession, leading the world in the discipline of surgical oncology. His pioneering accomplishments in various roles have been well documented. Scientists, clinicians, students, and patients benefited from his contributions to the management of malignant diseases, particularly melanoma. His many attributes in pursuing the goal to cure malignant diseases are well known. Br...
Source: Clinical Breast Cancer - July 31, 2023 Category: Cancer & Oncology Authors: S David Nathanson Ian Wood Source Type: research
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
EClinicalMedicine. 2023 Jun 29;61:102044. doi: 10.1016/j.eclinm.2023.102044. eCollection 2023 Jul.ABSTRACTBACKGROUND: The prospective multicentre observational INVIDIa-2 study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving immune checkpoint inhibitors (ICI). In this secondary analysis of the original trial, we aimed to assess the outcomes of patients to immunotherapy based on vaccine administration.METHODS: The original study enrolled patients with advanced solid tumours receiving ICI at 82 Italian Oncology Units from Oct 1, 2019, to Jan 31, 2020. The trial's pri...
Source: Cancer Control - July 12, 2023 Category: Cancer & Oncology Authors: Melissa Bersanelli Elena Verzoni Alessio Cortellini Raffaele Giusti Lorenzo Calvetti Paola Ermacora Marilena Di Napoli Annamaria Catino Valentina Guadalupi Giorgia Guaitoli Vieri Scotti Francesca Mazzoni Antonello Veccia Pamela Francesca Guglielmini Fabia Source Type: research
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
EClinicalMedicine. 2023 Jun 23;61:102043. doi: 10.1016/j.eclinm.2023.102043. eCollection 2023 Jul.ABSTRACTBACKGROUND: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunotherapy combined with antiangiogenic therapy has been reported to have synergistic antitumor activity. Therefore, we evaluated the efficacy and safety of camrelizumab plus famitinib in patients with RM-NPC who failed treatment with PD-1 inhibitor-containing regimens.METHODS: This multice...
Source: Cancer Control - July 7, 2023 Category: Cancer & Oncology Authors: Xi Ding Yi-Jun Hua Xiong Zou Xiao-Zhong Chen Xi-Mei Zhang Bei Xu Yan-Feng Ouyang Zi-Wei Tu Hui-Feng Li Chong-Yang Duan Wei-Jing Zhang Rui You You-Ping Liu Yong-Long Liu Qi Yang Pei-Yu Huang Shu-Ni Wang Jia Fan Ming-Yuan Chen Source Type: research
Primary role of type I interferons for the induction of functionally optimal antigen-specific CD8 < sup > + < /sup > T cells in HIV infection
EBioMedicine. 2023 Apr 12;91:104557. doi: 10.1016/j.ebiom.2023.104557. Online ahead of print.ABSTRACTBACKGROUND: CD8+ T cells equipped with a full arsenal of antiviral effector functions are critical for effective immune control of HIV-1. It has nonetheless remained unclear how best to elicit such potent cellular immune responses in the context of immunotherapy or vaccination. HIV-2 has been associated with milder disease manifestations and more commonly elicits functionally replete virus-specific CD8+ T cell responses compared with HIV-1. We aimed to learn from this immunological dichotomy and to develop informed strategi...
Source: Cancer Control - April 14, 2023 Category: Cancer & Oncology Authors: Mariela P Cabral-Piccin Laura Papagno Xavier Lahaye Federico Perdomo-Celis Stevenn Volant Eoghann White Val érie Monceaux Sian Llewellyn-Lacey R émi Fromentin David A Price Nicolas Chomont Nicolas Manel Asier Saez-Cirion Victor Appay Source Type: research
Fight Aging! Newsletter, March 20th 2023
This study also provides the potential for de novo generation of complex organs in vivo.
T Cells May Play a Role in the Brain Inflammation Characteristic of Neurodegenerative Conditions
https://www.fightaging.org/archives/2023/03/t-cells-may-play-a-role-in-the-brain-inflammation-characteristic-of-neurodegenerative-conditions/
Alzheimer's disease, and other forms of neurodegenerative condition, are characterized by chronic inflammation in brain tissue. Unresolved inflammatory signaling is disruptive of tissue structure and function. Here, researchers provide evidence for T cells to become involved in this...
Source: Fight Aging! - March 19, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A Look Back at 2022: Progress Towards the Treatment of Aging as a Medical Condition
At the end of 2022, we can reflect on the fact that we are steadily entering a new era of medicine, one in which mechanisms of aging are targeted rather than ignored. It is a profound change, one that will change the shape of a human life and ultimately the human condition by eliminating the greatest sources of suffering and death in the world. Year after year, we see increased funding, ongoing progress towards therapies capable of slowing aging or reversing aspects of aging, and a growing taxonomy of such potential therapies and their target mechanisms.
The view of aging in the medical community and public at large...
Source: Fight Aging! - December 30, 2022 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs
Fight Aging! Newsletter, September 26th 2022
This study examined the dose-response association between daily step count and intensity and incidence of all-cause dementia among adults in the UK. This was a UK Biobank prospective population-based cohort study (February 2013 to December 2015) with 6.9 years of follow-up (data analysis conducted May 2022). A total of 78,430 of 103,684 eligible adults aged 40 to 79 years with valid wrist accelerometer data were included. Registry-based dementia was ascertained through October 2021.
We found no minimal threshold for the beneficial association of step counts with incident dementia. Our findings suggest that approxima...
Source: Fight Aging! - September 25, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
SENS Research Foundation Annual Reports for 2022
The SENS Research Foundation has published its annual reports for 2022, for those interested. SENS, the Strategies for Engineered Negligible Senescence, is both (a) a laundry list of forms of cell and tissue damage that cause aging, with supporting evidence from the past century of scientific research into aging, and (b) a laundry list methods of intervention that should produce rejuvenation. Aging is damage accumulation, and rejuvenation is repair of that damage.
Funding for SENS programs, and initiatives to produce therapies based on the SENS view of damage repair, remain as relevant as ever. In fact, even more re...
Source: Fight Aging! - September 14, 2022 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
Fight Aging! Newsletter, August 1st 2022
In this study, we used the recently released Infinium Mouse Methylation BeadChip to compare such epigenetic modifications in C57BL/6 (B6) and DBA/2J (DBA) mice. We observed marked differences in age-associated DNA methylation in these commonly used inbred mouse strains, indicating that epigenetic clocks for one strain cannot be simply applied to other strains without further verification. Interestingly, the CpGs with highest age-correlation were still overlapping in B6 and DBA mice and included the genes Hsf4, Prima1, Aspa, and Wnt3a. Furthermore, Hsf4, Aspa, and Wnt3a revealed highly significant age-associated DNA methyla...
Source: Fight Aging! - July 31, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
